Emlino Tablet 10 mg+5 mg is a combination oral antidiabetic medication that contains Empagliflozin 10 mg and Linagliptin 5 mg. It is designed for the management of type 2 diabetes mellitus in adults who require enhanced glycemic control beyond monotherapy. This dual-action tablet targets two complementary pathways in blood sugar regulation, offering effective control of fasting and postprandial glucose levels while providing additional benefits such as weight management and cardiovascular protection.

Empagliflozin, an SGLT2 inhibitor, promotes the excretion of glucose via the kidneys, thereby reducing blood sugar levels. Linagliptin, a DPP-4 inhibitor, enhances incretin hormone activity to increase insulin secretion and suppress glucagon release, improving glucose regulation after meals. Together, these agents deliver a synergistic effect, making Emlino 10 mg+5 mg a reliable choice for patients who need combination therapy with once-daily dosing convenience.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Empagliflozin: 10 mg

• Linagliptin: 5 mg

Indications

Emlino Tablet 10 mg+5 mg is indicated for:

• Type 2 diabetes mellitus in adults requiring additional glycemic control

• Patients inadequately controlled on monotherapy with SGLT2 or DPP-4 inhibitors

• Adjunct to diet and exercise for improving HbA1c and fasting blood sugar

• Patients who may benefit from weight control and cardiovascular protection provided by Empagliflozin

• Simplifying therapy with a single once-daily combination tablet

Mechanism of Action

Emlino Tablet combines two mechanisms of action to improve blood glucose control:

1. Empagliflozin (SGLT2 Inhibitor):

   • Blocks the sodium-glucose co-transporter 2 in the renal tubules.

   • Promotes glucose excretion in urine, reducing plasma glucose levels.

   • Provides weight loss and blood pressure reduction, improving overall metabolic health.

2. Linagliptin (DPP-4 Inhibitor):

   • Inhibits the dipeptidyl peptidase-4 enzyme, preventing the breakdown of incretin hormones.

   • Enhances GLP-1 and GIP activity, increasing insulin release in response to meals.

   • Reduces glucagon secretion, decreasing hepatic glucose production.

   • Improves postprandial and fasting glucose control without significant hypoglycemia risk.

The combination of these actions ensures comprehensive glycemic management, addressing both renal glucose excretion and pancreatic insulin regulation.

Dosage and Administration

• Route: Oral

• Dosage: As prescribed by a registered physician

The usual dose is one tablet once daily, taken at the same time each day, with or without food. Patients should continue a balanced diet and regular exercise to maximize effectiveness. Blood glucose levels, kidney function, and overall metabolic status should be monitored regularly during therapy. Dose adjustments may be required based on patient response and tolerability.

Benefits of Emlino Tablet 10 mg+5 mg

• Dual-action therapy for enhanced glycemic control

• Reduces fasting and postprandial blood sugar

• Supports weight management and cardiovascular health

• Convenient once-daily oral dosing for improved adherence

• Minimal risk of hypoglycemia when used alone

• Improves HbA1c and overall diabetes management

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use only under medical supervision

• Contraindicated in type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to components

• Monitor for urinary tract infections, dehydration, hypotension, or hypoglycemia

• Caution in patients with renal or hepatic impairment

• Maintain adequate hydration to prevent volume depletion

• Inform physician of concomitant medications to avoid interactions

Storage Conditions

• Store below 30°C in a dry place

• Protect from light and moisture

• Keep out of reach of children

Pharmaceutical Category

Antidiabetic / SGLT2 Inhibitor + DPP-4 Inhibitor / Combination Therapy.